Royalty Pharma announces that as of 5:30 pm June 12, holders of approximately 276M Elan ADSs had voted on the Elan proposals. Based on its review of those votes, Royalty Pharma currently believes that Item 4 - Share Repurchase Program will be approved. However, Royalty Pharma believes that this proposal can still be voted down if a few shareholders change their vote. Royalty Pharma remains in active dialogue with Elan shareholders. If the offer lapses or is withdrawn, Irish takeover rules may prevent Royalty Pharma from making another unsolicited offer for 12 months.